Bayer Consumer Care Sale Remains Long-Term Option As Firm Restructures
This article was originally published in The Tan Sheet
Executive Summary
Bayer AG is leaving open the possibility that it could sell its consumer care division in the long-term, while emphasizing that it remains part of its "core" businesses for now.
You may also be interested in...
Bayer Changes Pharma Leadership On Eve Of U.S. Stock Listing
Bayer global pharmaceutical business head Wolfgang Plischke's range of experience within Bayer's different healthcare divisions is keeping with the company's plan to combine the divisions into a stand-alone unit
Bayer Changes Pharma Leadership On Eve Of U.S. Stock Listing
Bayer global pharmaceutical business head Wolfgang Plischke's range of experience within Bayer's different healthcare divisions is keeping with the company's plan to combine the divisions into a stand-alone unit
Bayer Changes Pharma Leadership On Eve Of U.S. Stock Listing
Bayer global pharmaceutical business head Wolfgang Plischke's range of experience within Bayer's different healthcare divisions is keeping with the company's plan to combine the divisions into a stand-alone unit